Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksElixirr International Regulatory News (ELIX)

Share Price Information for Elixirr International (ELIX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 570.00
Bid: 560.00
Ask: 580.00
Change: 0.00 (0.00%)
Spread: 20.00 (3.571%)
Open: 570.00
High: 570.00
Low: 570.00
Prev. Close: 570.00
ELIX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Acquisition of Insigniam LLC and Insigniam SAS

11 Dec 2023 07:00

RNS Number : 2566W
Elixirr International PLC
11 December 2023
 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED.

8 December 2023

 

ELIXIRR INTERNATIONAL PLC

 

Acquisition of Insigniam LLC and Insigniam SAS.

Elixirr International plc (AIM: ELIX) ("Elixirr", the "Company" and together with its subsidiaries, the "Group"), the established, global award-winning challenger consultancy, is pleased to announce the acquisition by its US subsidiary, Elixirr, Inc. of all of the issued and outstanding membership interests of Insigniam LLC ("Insigniam LLC"), and by Elixirr International plc, of the entire issued and outstanding shares of Insigniam SAS ("Insigniam Performance", and together with Insigniam LLC, "Insigniam"), for a maximum consideration payable of US$18.5 million (the "Consideration") (the "Acquisition").

 

Acquisition highlights

 

· Insigniam is a US-headquartered consultancy firm with 50+ personnel specialising in supporting clients and executives to define and navigate large scale change and transformation.

· This is the Group's fifth acquisition since its IPO in July 2020 and third in the US, enhancing the Group's presence in this key market.

· In the 12 months to November 2023 (unaudited), Insigniam recorded revenue of US$13.7m, normalised EBITDA of US$2.3m and normalised profit before tax of US$2.3m.

· The initial consideration represents a multiple of 5.7x 2023 LTM EBITDA, based off November 2023 LTM financials (unaudited).

· The transaction is immediately earnings-enhancing.

· The Acquisition brings specialist services in transformation, leadership alignment, cultural change, and executive coaching, complementing the Group's existing service offerings.

· In addition to an expansion of capabilities, Insigniam has deep expertise in additive industries for Elixirr, and in particular has built a reputation as market leaders within industries such as healthcare, biopharmaceuticals, life sciences, consumer and retail. Insigniam also has a significant presence and client-base in continental Europe, complementing the Group's presence in this region.

· Insigniam's top clients include Fortune 500 companies and household brands, many of which are maintained through the leadership's long-standing relationships with the C-suite, coupled with its unique service offering. 

· During due diligence and client interviews, Insigniam was found to be rated 43% better than their competition and has an NPS score of 66 - 85% of its clients report that Insigniam provides more value than any other consulting firm. Together with Insigniam, Elixirr will be able to enhance its existing service offering to its global client base.

· The US acquisition goodwill will be tax-deductible, resulting in an estimated tax benefit of US$2.8m-$4.3m to be realised over 15 years.

 

Information on Insigniam and reasons for the Acquisition

 

Insigniam helps companies navigate large-scale, complex change and transformation. Its offering includes leadership alignment, organisational transformation, cultural change and executive coaching, and its unique methodologies are used to break down performance barriers for C-suite teams across industries. Insigniam operates within a broadly unaddressed and in-demand white space in the market, through a dual focus on catalysing breakthrough change and achieving return on investment. This distinctive market opportunity is a key reason for the acquisition, especially when coupled with Insigniam's proven success at delivering for clients over its 35+ year history. Elixirr leadership believes that both firms' blue-chip clients stand to benefit from a joint proposition between Insigniam and Elixirr.

Insigniam was co-founded by Shideh Sedgh Bina and Nathan Owen Rosenberg, both of whom will continue to spearhead the growth of the business alongside Elixirr moving forward. Shideh and Nathan will join the Group as Elixirr partners, alongside Katerin Le Folcalvez and Jennifer Zimmer.

In the 12 months to November 2023 (unaudited), Insigniam recorded revenue of US$13.7m, normalised EBITDA of US$2.3m and normalised profit before tax of US$2.3m.

 

Consideration for the Acquisition

 

The Group acquired Insigniam for a maximum consideration payable of US$18.5 million. The Consideration consists of:

 

- Initial consideration of US$11.6 million, from Elixirr's existing cash balances;

- Initial consideration of US$1.5 million to be settled through the issue in December 2023 of 258,553 Elixirr International plc Ordinary shares at a price per share of £4.60 by 15 December 2023; and

- Deferred consideration of up to US$5.4 million in either cash or Ordinary Shares of Elixirr with, at a minimum, 33% of the deferred consideration being satisfied in cash. This is contingent on Insigniam achieving both revenue growth and EBITDA margin targets in financial periods up to 31 December 2026.

 

Based off November 2023 LTM financials (unaudited), this constitutes a Day 1 EV/EBITDA multiple of 5.7x, and a maximum EV/EBITDA multiple of 8.1x if all deferred consideration is earned over the three year period.

 

The Ordinary Shares will be subject to one-year lock-in arrangements and limitations on the Ordinary Shares that each seller can sell in each of the following three years under nominee agreements.

Following the acquisition of Insigniam, Elixirr will have net cash of approximately £13.5 million.

 

Partner Promotions

As part of its strategy to align incentives for senior personnel, Elixirr is pleased to announce that three recently promoted Partners will each be subscribing for 107,527 Ordinary Shares in the Company at a £4.65 share price. The Ordinary Shares issued to the new Partners will be subject to one-year lock-in arrangements and limitations on the Ordinary Shares that each Partner can sell in each of the following four years. In total, Elixirr will issue an additional 322,581 Ordinary Shares to promoted Partners.

 

Admission and Total Voting Rights

As referred to above, in total Elixirr will issue 581,134 Ordinary Shares ("New Shares"). The New Shares will rank pari passu with the Company's existing issued Ordinary Shares. The New Shares will be issued pursuant to the Company's existing outstanding shareholder authorities. Application will be made to the London Stock Exchange for the New Shares to be admitted to trading on AIM ("Admission") and it is expected that Admission will become effective at 8.00 a.m. on 15th December 2023.

After Admission, the total number of Ordinary Shares in issue will be 47,272,811 and the total number of voting rights will therefore be 47,272,811. Following Admission, this figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

Founder & CEO of Elixirr, Stephen Newton said:

"I am always exceptionally proud to expand our team, and finding the right people to bring into the group is no small task. Our M&A team works tirelessly to find companies that not only broaden what we're able to offer clients but improve the work we're already doing with them. We also look for those who share in Elixirr's ethos, entrepreneurial spirit and desire to create meaningful change - and in Insigniam we have found exactly that. I look forward to seeing the impact of their team's unique approach to consulting - which looks deeply into the areas many consultancies often overlook or don't have true capability to impact. They are the undisputed market leaders in transformation and organisational change, and this is something that will be extremely valuable to both our current and future clients. By combining our services and expertise, from strategy through to execution, we are very well-positioned to provide full end-to-end services to our collective clients in a more impactful, dynamic way."

Co-Founder of Insigniam, Shideh Sedgh Bina said:

 

"We are thrilled that Elixirr not only expands our ability to provide an enhanced range of services for our clients, but also enables us to partner with C-suite executives to design and execute on their fit-for-21st-century-agenda. The Elixirr disrupter mindset, entrepreneurial culture and leadership team are perfectly aligned with our commitment to serve our clients to deliver remarkable results. Like Insigniam, Elixirr is not afraid to challenge convention, talk straight and disrupt the status quo. Elixirr and Insigniam both hold dear an ethos of deep client service, and we believe that together, combining the best of 'being human' with technology and data, we will deliver dramatic new outcomes for our clients." 

Co-Founder of Insigniam, Nathan Owen Rosenberg said:

"Insigniam's combination with Elixirr gives our clients a range of services that, in my scan of the market, has not been available. Already, the Elixirr partners and Insigniam partners are collaborating to catalyse new value for our combined clients, as well as working on a new set of offerings. Literally, we can now offer the full range of expertise and services needed to transform a CEO's agenda into reality. Clients will see new capabilities to fulfill their intentions. We now provide extraordinary value to the CEO and his or her team and to each executive in the C-suite, beyond what either firm could offer before the combination."

The person responsible for arranging the release of this announcement on behalf of the Company is Nicholas Willott, Finance Director and Company Secretary of the Company.

 

For further information please contact:

Elixirr International plc

Stephen Newton, CEO

Graham Busby, CFO

 

 

 

 

Public and Investor Relations contacts:

investor-relations@elixirr.com 

 

Cavendish Capital Markets Ltd (Nominated Adviser & Joint Broker)

Stephen Keys, Charlie Beeson (Corporate Finance),

Sunila De Silva (ECM)

 

Investec Bank plc (Joint Broker)

Carlton Nelson, Henry Reast (Corporate Broking)

 

 

 

 

 

+44 (0) 20 7220 0500

 

 

 

+44 (0) 20 7597 4000

About Elixirr International plc

Elixirr is an established global award-winning management consultancy, challenging the larger consultancies by delivering innovative and bespoke solutions to a repeat, globally-recognised client base.

Elixirr was founded in 2009, by Stephen Newton, Graham Busby, Ian Ferguson, Andy Curtis and Mark Goodyear, experienced business advisors who identified a market opportunity to provide bespoke, personal services as a 'challenger' to the traditional consultancy businesses in the market. Elixirr guides its clients to overcome challenges such as: future-proofing against technological disruption; development and roll-out of innovative new propositions, products and services; incubating new businesses; navigating a more complex and multinational regulatory environment; and project management and implementation of major change programmes.

 

General

This announcement is for information purposes only and does not constitute or form part of any offer to issue or sell, or the solicitation of an offer to acquire, purchase or subscribe for, any securities in any jurisdiction and should not be relied upon in connection with any decision to subscribe for or acquire ordinary shares in the capital of the Company. In particular, this announcement does not constitute or form part of any offer to issue or sell, or the solicitation of an offer to acquire, purchase or subscribe for, any securities in the United States.

This announcement has been issued by, and is the sole responsibility of, the Company. No person has been authorised to give any information or to make any representations other than those contained in this announcement and, if given or made, such information or representations must not be relied on as having been authorised by the Company.

No statement in this announcement is intended to be a profit forecast or profit estimate and no statement in this announcement should be interpreted to mean that earnings per share of the Company for the current or future financial years would necessarily match or exceed the historical published earnings per share of the Company.

This announcement may include statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the terms "believes", "estimates", "plans", "projects", "anticipates", "expects", "intends", "may", "will", "would" or "should" or, in each case, their negative or other variations or comparable terminology. These forward-looking statements include matters that are not historical facts. They appear in a number of places throughout this announcement and include statements regarding the directors of the current Company's intentions, beliefs or expectations concerning, among other things, the Company's results of operations, financial condition, liquidity, prospects, growth, strategies, and the Company's markets. By their nature, forward-looking statements involve risk and uncertainty because they relate to future events and circumstances. Actual results and developments could differ materially from those expressed or implied by the forward-looking statements. Forward-looking statements may and often do differ materially from actual results. Any forward-looking statements in this announcement are based on certain factors and assumptions, including the directors of the Company's current view with respect to future events and are subject to risks relating to future events and other risks, uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy and liquidity. Whilst the directors of the Company consider these assumptions to be reasonable based upon information currently available, they may prove to be incorrect. Save as required by applicable law, the AIM Rules or the Disclosure Guidance and Transparency Rules of the Financial Conduct Authority, the Company undertakes no obligation to release publicly the results of any revisions to any forward-looking statements in this announcement that may occur due to any change in the directors of the Company's expectations or to reflect events or circumstances after the date of this announcement.

Neither the content of the Company's website nor any website accessible by hyperlinks to the Company's website is incorporated in, or forms part of, this announcement.

Certain figures contained in this announcement, including financial information, have been subject to rounding adjustments. Accordingly, in certain instances, the sum or percentage change of the numbers contained in this announcement may not conform exactly with the total figure given.

All references to time in this announcement are to London time, unless otherwise stated.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ACQFFFESSEDSEIE
12
Date   Source Headline
24th Apr 20247:00 amRNSGrant of Share Options
22nd Apr 20247:00 amRNSFinal Results
8th Apr 20247:00 amRNSNotice of FY 23 Results and Investor Presentation
26th Jan 20247:00 amRNSDirector Dealing
8th Jan 20247:00 amRNSTrading Update and Change to Dividend Policy
11th Dec 20237:00 amRNSAcquisition of Insigniam LLC and Insigniam SAS
18th Sep 20237:00 amRNSInterim Results
18th Sep 20237:00 amRNSAcquisition of Responsum, Inc.
13th Jun 202310:45 amRNSResult of AGM
24th May 20231:31 pmRNSHolding(s) in Company
19th May 20237:00 amRNSPosting of Annual Report and Accounts
10th May 20233:00 pmRNSDirector/PCA Dealings
26th Apr 20237:00 amRNSGrant of Share Options
12th Apr 20237:00 amRNSAppointment of Joint Corporate Broker
4th Apr 20233:00 pmRNSDirector Dealing
3rd Apr 20239:15 amRNSDirector Dealing
3rd Apr 20237:00 amRNSFinal Results
28th Mar 20237:00 amRNSInvestor Presentation
27th Feb 20239:05 amRNSSecond Price Monitoring Extn
27th Feb 20239:00 amRNSPrice Monitoring Extension
27th Feb 20237:00 amRNSTrading Update
24th Feb 20232:05 pmRNSSecond Price Monitoring Extn
24th Feb 20232:00 pmRNSPrice Monitoring Extension
24th Feb 202311:05 amRNSSecond Price Monitoring Extn
24th Feb 202311:00 amRNSPrice Monitoring Extension
29th Nov 20221:15 pmRNSInvestor Presentation
11th Nov 20227:00 amRNSDirector Dealing
20th Oct 20227:00 amRNSPCA Dealing
6th Oct 20227:00 amRNSPurchase of Shares by Employee Benefit Trust
20th Sep 20227:00 amRNSInterim Results
12th Sep 20227:00 amRNSNotice of Interim Results
29th Jul 20224:41 pmRNSSecond Price Monitoring Extn
29th Jul 20224:35 pmRNSPrice Monitoring Extension
11th Jul 20221:45 pmRNSPDMR/PCA Dealing
7th Jul 202211:15 amRNSPCA Dealing
13th Jun 20221:00 pmRNSResult of AGM
19th May 20227:00 amRNSPosting of Annual Report & Accounts
29th Apr 20224:07 pmRNSResult of Secondary Placing
28th Apr 20224:06 pmRNSProposed Secondary Placing
8th Apr 20224:15 pmRNSDirector/PDMR Shareholding
4th Apr 20227:00 amRNSFinal Results
18th Mar 20227:00 amRNSAcquisition of iOLAP and FY2022 Earnings
1st Feb 20227:00 amRNSTrading Update
30th Nov 20217:00 amRNSDirector/PDMR Shareholding
13th Oct 202111:41 amRNSResult of Secondary Placing
13th Oct 20217:00 amRNSProposed Secondary Placing
27th Sep 20217:00 amRNSInterim Results
17th Jun 20218:13 amRNSDirector/PDMR Shareholding
16th Jun 202112:21 pmRNSResult of AGM
16th Jun 20217:00 amRNSAGM Statement
12

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.